Innovative Technologies that Yield Improved Treatments - Research Report on Mettler-Toledo, Ironwood, Covance, Teleflex and WuXi

NEW YORK, June 26, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Mettler-Toledo International, Inc. (NYSE: MTD), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Covance Inc. (NYSE: CVD), Teleflex Incorporated (NYSE: TFX) and WuXi PharmaTech (Cayman) Inc. (NYSE: WX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Mettler-Toledo International, Inc. Research Report

On June 20, 2013, Mettler-Toledo International, Inc. (Mettler-Toledo) announced that it has released two new titration brochures, the "Selected Titration Methods for the Food and Beverages Industry", and the thoroughly revised Karl Fischer Applications Brochure "Methods for Water Content Determination". The releases aim to assist laboratory personnel in method development and implementation. It also explains the chemistry behind Karl Fischer, food and beverage titrations and give practical advice for sample and reagent handling. As per the Company, the Food and Beverage (F&B) industry is subject to regulations covering the entire production process for the benefit of food safety, consumer protection and international trade. And hence, well defined analytical reference methods are needed at all stages of the production process and content determination by titration is a widely used analytical technique. The Full Research Report on Mettler-Toledo International, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:  http://www.WSReports.com/r/full_research_report/a364_MTD]

--

Ironwood Pharmaceuticals Inc. Research Report

On June 13, 2013, Ironwood Pharmaceuticals Inc. (Ironwood) along with Almirall, S.A., announced the launch of Constella, the first approved prescription therapy in a new class of treatments for adults suffering from moderate to severe IBS-C (Irritable Bowel Syndrome with Constipation) in Europe. "The availability of linaclotide is excellent news for the one-third of adult IBS patients that have constipation. The symptoms associated with the condition can negatively impact the lives of patients. A targeted prescription treatment specifically for IBS-C is extremely welcome for both appropriate patients and physicians alike who can now better manage this unpleasant, chronic condition", said Professor Eamonn Quigley, Gastroenterologist. The Company informed that Constella is now available in Germany, the UK and Nordic countries and is expected to be launched in several other European countries in 2013. The Full Research Report on Ironwood Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/d5cb_IRWD]

--

Covance Inc. Research Report

On June 18, 2013, Covance Inc. (Covance) announced that a partnership between the Company and Battle Creek Unlimited received the Best New Partnership, Merger or Acquisition Award at the 2013 Nutraceutical Business & Technology Awards, held recently in Geneva, Switzerland. Covance and Battle Creek Unlimited were recognized for an innovative partnership that is helping to promote excellence in food science, shape the next generation of food scientists and help transform Battle Creek into a food science, innovation and growth-oriented community. The Full Research Report on Covance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/5499_CVD]

--

Teleflex Incorporated Research Report

On June 10, 2013, Teleflex Inc. (Teleflex) announced that it has received FDA 510(k) clearance to market ARROW NextStep Retrograde Femoral Length Dialysis Catheters, which is designed for clinical ease of insertion and sustained high flow rates. "Providing clinicians with the ARROW NextStep Femoral Length Catheters continues a series of new product introductions that demonstrates our commitment to enhance patient outcomes and improve ease of use for clinicians," said Linda Beneze, President and General Manager, Specialty Division, Teleflex. Teleflex asserts that ARROW NextStep Retrograde Femoral Length Catheters further strengthens the NextStep Hemodialysis Catheter portfolio of the Company. The Full Research Report on Teleflex Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/9f7f_TFX]

--

WuXi PharmaTech (Cayman) Inc. Research Report

On June 16, 2013 WuXi PharmaTech (Cayman) Inc. (WuXi) announced that Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate (ADC) targeting Her2-positive breast cancer. As per the agreement, WuXi will provide integrated services for ARX788, including the development and manufacturing of the toxin, antibody and ADC, pre-clinical development and clinical trials. "Our collaboration with Ambrx and ZMC on ARX788 is another example of how WuXi's comprehensive, integrated, open-access R&D services platform enables our partners to develop innovative products efficiently and cost-effectively to benefit the world's patients," said Dr. Ge Li, Chairman and Chief executive Officer of WuXi. "We are very pleased to offer our partners integrated services at global standards ranging from toxins to antibodies, from CMC development to pre-clinical studies, from regulatory strategy to clinical trials." The Full Research Report on WuXi PharmaTech (Cayman) Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/d375_WX]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Reports